Mon08032020

Robins Global News & Noticias



COVID-19 Map Tracker | COVID-19 News Features


  • Career Exam Study
    Career Exam Study
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News

RobinsPost News Network

+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2020 Financial Results and Business Updates


CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Friday, August 7, 2020 at 8:00 a.m. ET to report financial results for the second quarter ended June 30, 2020 and provide business updates. 

To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 1081289. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.

Contact:

Investor & Media Contact
Sarah Carmody, 617-844-8577
This email address is being protected from spambots. You need JavaScript enabled to view it. 




Posted: 2020-07-31 12:00:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.





Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2020 Financial Results and Business Updates | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Hyatt Reports Second-Quarter 2020 Results

Mon, 03 Aug 2020 13:30:00 GMT

CHICAGO--(Business Wire)--Hyatt Hotels Corporation ("Hyatt" or the "Company") (NYSE: H) today reported second-quarter 2020 financial results. Net loss attributable to Hyatt was $236 million, or $2.33 ...

Virgin Galactic Announces Second Quarter 2020 Financial Results

Mon, 03 Aug 2020 13:05:00 GMT

Virgin Galactic Holdings, Inc. (NYSE: SPCE) (“Virgin Galactic” or “the Company”), a vertically integrated aerospace and space travel company, today an ...

Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates

Mon, 03 Aug 2020 13:01:00 GMT

Successfully completed Phase 1b trial of AVB-500 in Platinum Resistant Ovarian Cancer with encouraging clinical data showing 60% ORR in the subpopulation that has not previously been treated with ...

Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

Mon, 03 Aug 2020 06:25:00 GMT

IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively   - -  Completed $24 million equity private placement ...

Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates

Mon, 03 Aug 2020 04:46:00 GMT

(GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, ...

Related News Story Videos From Youtube






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2020 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.